Immix Biopharma Reports Q3 2026 Financial Results and Cash Runway
Immix Biopharma (IMMX) has released its financial results for the third quarter ending September 30, 2026. The company reported a strong liquidity position, holding $340.9 million in cash, cash equivalents, and marketable securities. Based on current spending levels, which included $15.9 million in operating expenses for the quarter, management expects this capital to provide an operational runway extending into mid-2028. This financial stability provides a significant buffer for ongoing research and development activities.
Tickers: $IMMX
Topics: cash_position liquidity operating_expenses
Read the full article at Seeking Alpha
Part of the story Palvella Reports Q3 2026 Financial Results and FDA Priority Review for QTORIN (7 articles)